spacer
home > ebr > spring 2018 > from pharma to beauty
PUBLICATIONS
European Biopharmaceutical Review

From Pharma to Beauty

We are surrounded by microbes: in the air we breathe, our environment, and our body itself, which harbours billions of microbes in our gut, skin, eyes, urinary tract, etc. They interact with the body’s main functions and particularly its natural defences. Back in the 1970s, doctors had the idea to use parts of microbes (bacterial lysates) to stimulate immune defences. These mixtures of inactivated pathogenic bacteria were able to protect the body by stimulating both types of immune response: acquired and innate. Today, as people are looking for holistic approaches to protect their health, bacterial lysates have gained renewed interest. Their modes of actions are better understood as they have the ability to stimulate the immune defences, but also to reduce inflammatory reactions when the immune system is overloaded. Thus, their scope of applications has grown and they can currently be used in various areas: as drugs for the prevention of respiratory infections, but also in dermo-cosmetic applications.

What Are Bacterial Lysates?

Bacterial lysates are mixtures of inactivated, killed bacteria that may contain all the components of the bacteria cells (soluble and insoluble). In drug applications, bacterial lysates may be derived from inactivated pathogenic bacteria; the principle is to trigger immune surveillance thanks to the antigens derived from the bacteria and to up-regulate immune defences to prevent and help fight infections. In other cases, such as certain cosmetic applications, the bacteria used may be commensal or bacteria selected from the environment.

In the case of immunostimulant drugs, polyvalent bacterial lysates are prepared from different species of bacteria. Each strain is grown independently in fermenters, harvested, then inactivated by heat, and lysed using either mechanical or chemical lysis. Chemical lysates are obtained by the action of chemical alkaline substances that may denature the antigenic structures. Mechanical bacterial lysates are obtained by high pressure, which preserves the particulate antigens. This is of importance as the preservation of the antigenic structure warrantees a stronger immune response. After lyophilisation, the different lysates are mixed in fixed proportions, and formulated into finished products (sub-lingual tablets, capsules, sachets, and so on).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
A specialist in microbiology and microbial applications, Dr Christian Sanchez has headed the specialty division of Lallemand group from 1983 to 2011, where he was instrumental in the development of the group activities in key markets such as oenology, animal and human nutrition, and pharma applications before supporting the recent development of the plant care division of the company. Today, as Senior Vice President and Special Advisor, he advises the company on new developments for microbial solutions, such as the cosmetics market. Christian holds a Doctorate in biological science from Toulouse University, France, and held various positions in teaching and research at Toulouse University before joining the biotechnology industry. 

Maxence de Villemeur is Marketing and Sales Manager for Lallemand Pharma since October 2010 and is in charge of global business and marketing development of polyvalent mechanical bacterial lysates. Prior to this, she was Product Manager in the health division of Lallemand. Maxence has over 15 years of marketing and business experience in international healthcare and pharma markets. She holds an MBA in international management from ESC Clermont-Ferrand, France, and graduated in product development engineering from Cergy-Pontoise Industrial Biology Engineering School at EBI, France.
spacer
Dr Christian Sanchez
spacer
spacer
spacer
Maxence de Villemeur
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Show germs the final curtain

Teknomek’s PVC strip curtains are renowned for helping reduce hygiene risk by keeping differently graded areas within cleanrooms separate. The company has now extended this protection by adding anti-microbial protection embedded within the PVC to prevent the growth of bacteria, including MRSA, and further minimising the risk of cross-contamination. The anti-microbial curtains are built to last, with silver ions incorporated during the manufacturing process, providing significantly greater microbial resistance. The hard-wearing curtains suitable for use in temperatures of +38°C to - 10°C.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Clinical Innovation Partnerships 2018

3-4 July 2018, Radisson Blu Hotel, Zurich Airport

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement